The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview.

Détails

ID Serval
serval:BIB_3E85269984C3
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview.
Périodique
Cancer biology & medicine
Auteur⸱e⸱s
Quiñonero F., Mesas C., Doello K., Cabeza L., Perazzoli G., Jimenez-Luna C., Rama A.R., Melguizo C., Prados J.
ISSN
2095-3941 (Print)
ISSN-L
2095-3941
Statut éditorial
Publié
Date de publication
11/2019
Peer-reviewed
Oui
Volume
16
Numéro
4
Pages
688-699
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Pancreatic ductal adenocarcinoma (PDAC) has one of the highest mortality rates among all cancer types. Its delayed diagnosis precludes curative resection, thus most of the current therapies against PDAC are based on chemo- and radiotherapy. Unfortunately, these strategies are insufficient to improve its poor prognosis. Despite the advances made in chemotherapy (e.g. nab-paclitaxel and gemcitabine), many patients with PDAC are unable to benefit from them due to the rapid development of drug resistance. Currently, more than 165 genes have been found to be implicated in drug resistance of pancreatic tumors, including different integrins, mucins, NF-κB, RAS and CXCR4. Moreover, drug resistance in PDAC is thought to be mediated by the modulation of miRNAs (e.g. miRNA-21, miRNA-145 and miRNA-155), which regulate genes that participate in cell proliferation, invasion and metastasis. Finally, cancer stem cells are intimately related to drug resistance in PDAC due to their ability to overexpress ABC genes -involved in drug transport-, and enzymes such as aldehyde dehydrogenases -implicated in cellular drug metabolism- and poly (ADP-ribose) polymerases -involved in drug-induced DNA damage repair. Understanding the mechanisms involved in drug resistance will contribute to the development of efficient therapeutic strategies and to improve the prognosis of patients with PDAC.
Mots-clé
Pancreatic ductal adenocarcinoma, cancer stem cells, chemotherapy, drug resistance, therapeutic strategies
Pubmed
Web of science
Open Access
Oui
Création de la notice
10/01/2020 15:40
Dernière modification de la notice
15/01/2024 16:54
Données d'usage